Cellares closed a $257 million Series D financing to expand its automated cell‑therapy manufacturing facilities and accelerate a planned commercial launch ahead of a targeted 2027 IPO. The funding will help the company deploy its integrated automation platform to produce engineered cell therapies at scale. Cellares builds modular, automated manufacturing suites intended to reduce operator burden and increase reproducibility for CAR‑T and other cell therapies. The raise underscores continued investor appetite for CDMO‑style solutions that address cell‑therapy manufacturing constraints and the industry’s need to scale advanced therapy production.